SCHEMBL1648529

SCHEMBL1648529

CCc1ccc(CS(=O)(=O)c2ccccc2)c(C(=O)O)c1-c1ccn(C)n1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.37
KDM4E B2RXH2 2/20 0.37
KMT2A Q03164 3/20 0.36
HSD11B1 P28845 3/20 0.36
PSIP1 O75475 1/20 0.36
TSHR P16473 2/20 0.35
HSD17B10 Q99714 1/20 0.35
JMJD6 Q6NYC1 2/20 0.34
METAP2 P50579 1/20 0.33
POLB P06746 2/20 0.32
DPP4 P27487 1/20 0.32
MAPT P10636 1/20 0.32
MPI P34949 1/20 0.32
HTT P42858 1/20 0.32
APOBEC3G Q9HC16 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1648266 0.89 LMNA (0.38) ALDH1A1SMN1; SMN2PTGDR2KMT2AHSD11B1
SCHEMBL1648549 0.83 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2PTGDR2KDM4EKMT2A
SCHEMBL1647751 0.79 HSD11B1 (0.36) ALDH1A1SMN1; SMN2PTGDR2KDM4EKMT2A
SCHEMBL1648038 0.78 ALDH1A1 (0.38) ALDH1A1SMN1; SMN2PTGDR2KMT2AHSD11B1
SCHEMBL1650141 0.78 ALDH1A1 (0.37) ALDH1A1SMN1; SMN2PTGDR2KDM4EKMT2A
SCHEMBL28104284 0.74 PSIP1 (0.46) ALDH1A1KMT2AHSD11B1PSIP1TSHR
SCHEMBL1648340 0.71 METAP2 (0.50) ALDH1A1KMT2AHSD11B1PSIP1TSHR
SCHEMBL1649006 0.70 POLB (0.37) ALDH1A1SMN1; SMN2KMT2AHSD11B1PSIP1
SCHEMBL31555655 0.70 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2KDM4EKMT2AHSD11B1
SCHEMBL1649329 0.69 METAP2 (0.54) ALDH1A1KDM4EKMT2ATSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2486004-B1 SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY ZAFGEN INC (US) 2017-05-03 EP claimed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US claimed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US claimed
EP-2486004-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME Zafgen Corporation (US) 2012-08-15 EP claimed
WO-2011044506-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2011-04-14 WO claimed
EP-2486004-B1 SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY ZAFGEN INC (US) 2017-05-03 EP disclosed
EP-2486004-B1 SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY ZAFGEN INC (US) 2017-05-03 EP disclosed
US-20160051531-A1 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN INC (US) 2016-02-25 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
EP-2486004-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME Zafgen Corporation (US) 2012-08-15 EP disclosed
WO-2011044506-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2011-04-14 WO disclosed
WO-2011044506-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160051531-A1 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME METAP2, DNPEP, STS ALDH1A1 360/4885SMN1; SMN2 2123/4885PTGDR2 2007/4885
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same METAP2, DNPEP, STS ALDH1A1 360/4885SMN1; SMN2 2123/4885PTGDR2 2007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.